Form 8-K - Current report:
SEC Accession No. 0001601485-25-000006
Filing Date
2025-01-22
Accepted
2025-01-22 07:33:06
Documents
17
Period of Report
2025-01-22
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K angn-20250122.htm   iXBRL 8-K 23443
2 EX-99.1 fdatypebpr_final.htm EX-99.1 11743
6 fdatypebpr_final001.jpg GRAPHIC 233117
7 fdatypebpr_final002.jpg GRAPHIC 258706
8 fdatypebpr_final003.jpg GRAPHIC 188742
  Complete submission text file 0001601485-25-000006.txt   1106900

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT angn-20250122.xsd EX-101.SCH 1870
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT angn-20250122_lab.xml EX-101.LAB 22786
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT angn-20250122_pre.xml EX-101.PRE 13130
20 EXTRACTED XBRL INSTANCE DOCUMENT angn-20250122_htm.xml XML 2907
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

EIN.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39990 | Film No.: 25543893
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)